Background Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE) is scarce, despite frequent and often off-label use. Patient registries provide valuable evidence for the effects of treatments under real-world conditions that can inform treatment guidelines, give the opportunity for health economic evaluation and the evaluation of quality of care, as well as pharmacogenetic and dynamic research, which cannot be adequately addressed in clinical trials. Objectives The TREatment of ATopic eczema (TREAT) Registry Taskforce aims to seek international consensus on a core set of domains and items ('what to measure') for AE research registries, using a Delphi approach. Methods Participants from six stakeholder gr...
Importance: A recent expert consensus exercise emphasized the importance of developing a global netw...
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmac...
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmac...
Background: Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE...
BACKGROUND:Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE)...
Background Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE)...
BackgroundPatients with moderate-to-severe atopic eczema (AE) often require photo- or systemic immun...
Background: Comparative, real-life and long-term evidence on the effectiveness and safety of phototh...
Background Comparative, real-life and long-term evidence on the effectiveness and safety of photothe...
Background: The TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative internation...
BACKGROUND: Comparative, real-life and long-term evidence on the effectiveness and safety of phototh...
Background: A long-term prospective observational safety study is essential to characterize fully th...
International audienceBackground A long-term prospective observational safety study is essential to ...
Background: For many years dermatologists have had access to few therapies for patients with moderat...
There is wide variation in the use of outcome measures for eczema. We performed a three-stage web-ba...
Importance: A recent expert consensus exercise emphasized the importance of developing a global netw...
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmac...
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmac...
Background: Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE...
BACKGROUND:Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE)...
Background Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE)...
BackgroundPatients with moderate-to-severe atopic eczema (AE) often require photo- or systemic immun...
Background: Comparative, real-life and long-term evidence on the effectiveness and safety of phototh...
Background Comparative, real-life and long-term evidence on the effectiveness and safety of photothe...
Background: The TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative internation...
BACKGROUND: Comparative, real-life and long-term evidence on the effectiveness and safety of phototh...
Background: A long-term prospective observational safety study is essential to characterize fully th...
International audienceBackground A long-term prospective observational safety study is essential to ...
Background: For many years dermatologists have had access to few therapies for patients with moderat...
There is wide variation in the use of outcome measures for eczema. We performed a three-stage web-ba...
Importance: A recent expert consensus exercise emphasized the importance of developing a global netw...
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmac...
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmac...